MIB-626 + Exercise for Healthy Adults
Trial Summary
Do I have to stop taking my current medications for the trial?
You may need to stop taking certain supplements, especially those containing niacin or its related compounds, at least 2 weeks before starting the trial. Herbal supplements and performance-enhancing substances are also prohibited. If you're taking any of these, you'll need to stop before participating.
What data supports the effectiveness of the treatment MIB-626 + Exercise for Healthy Adults?
Research on exercise in people with multiple sclerosis (MS) shows that exercise can improve fitness, quality of life, and even have neuroprotective effects. While this research is specific to MS, it suggests that exercise, a component of the MIB-626 + Exercise treatment, can have significant health benefits.12345
Is MIB-626 + Exercise safe for humans?
How does the drug MIB-626 differ from other treatments for improving physical activity in healthy adults?
MIB-626, also known as β-Nicotinamide Mononucleotide (NMN), is unique because it is a compound that may enhance cellular energy production and improve physical performance, potentially offering benefits beyond regular exercise alone. Unlike standard exercise routines, MIB-626 could provide additional support for energy metabolism, making it a novel approach for boosting physical activity in healthy adults.1112131415
What is the purpose of this trial?
A single-center, randomized, placebo-controlled study in community dwelling, healthy, regularly exercising, highly physically fit men and women, 19 to 40 years. Eligible participants will be randomized to receive either 1000 mg NMN or placebo twice daily for 10 weeks.
Research Team
Shalender Bhasin, MD
Principal Investigator
Brigham and Women's Hospital
Eligibility Criteria
This trial is for healthy, fit individuals aged 19-40 who regularly engage in high-intensity exercise and meet specific fitness criteria (VO2max of at least 40 mL/kg/min). Participants must have a BMI between 18.5 and 32, be willing to undergo intensive training or maintain usual activity based on group assignment, and not plan to become pregnant. Exclusions include certain medical conditions, use of performance-enhancing drugs or prohibited medications, competing athletes, and contraindications to MRI/MRS.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive either 1000 mg NMN or placebo twice daily for 10 weeks, with or without a high-intensity exercise program
Follow-up
Participants are monitored for safety and effectiveness after treatment
Treatment Details
Interventions
- High-Intensity Multi-Dimensional Exercise Training Program
- MIB-626
- Placebo
- Usual Physical Activity
Find a Clinic Near You
Who Is Running the Clinical Trial?
Metro International Biotech, LLC
Lead Sponsor